Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

LTRN
Lantern Pharma Inc. Common Stock
stock NASDAQ

At Close
Jul 8, 2025 3:59:41 PM EDT
3.51USD+11.429%(+0.36)3,505,792
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 9, 2025 8:07:30 AM EDT
3.64USD+2.825%(+0.10)19,970
After-hours
Jul 8, 2025 4:52:30 PM EDT
3.49USD-0.570%(-0.02)4,377
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
09:45AM EST  Benzinga Announces This Week's All Access Guests   Benzinga
Jan 25, 2022
07:32AM EST  LTRN: Multiple Collaborations Illuminating Way Forward   Benzinga
Jan 24, 2022
07:04AM EST  Lantern Pharma Receives Rare Pediatric Disease And Orpan Drug Designations For LP-184 For The Treatment Of Atypical Teratoid Rhabdoid Tumor, An Aggressive And Rapidly Growing Form Of Cancer Of The Central Nervous System   Benzinga
07:01AM EST  LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System   PR Newswire
Jan 18, 2022
06:33AM EST  Lantern Pharma Announces Collaboration & Research Agreement With The Danish Cancer Society Research Center To Support Clinical Development Of Drug Candidates, LP-100 And LP-184, In Solid Tumors   Benzinga
06:30AM EST  Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors   PR Newswire
Jan 12, 2022
06:09AM EST  Lantern Pharma Expands Oncology Collaboration With National Cancer Institute   Benzinga
06:06AM EST  Lantern Pharma Expands Collaboration With National Cancer Institute For Drug Candidates LP-184 & LP-284   RTTNews
06:04AM EST  Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284   PR Newswire
Jan 4, 2022
09:29AM EST  Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference   PR Newswire
Dec 14, 2021
09:04AM EST  Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting   PR Newswire
09:03AM EST  Lantern Pharma Presents Positive Data On The Effectiveness Of LP-284 In Hematologic Cancers   RTTNews
Nov 22, 2021
09:11AM EST  Lantern Pharma To Repurchase Up To $7 Mln Of Common Stock   RTTNews
09:05AM EST  Lantern Pharma Announces $7M Share Repurchase Program   Benzinga
Nov 12, 2021
09:41AM EST  Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day   PR Newswire
Nov 11, 2021
09:16AM EST  Lantern Pharma Announces Abstract On Effectiveness Of LP-184 In Glioblastoma Accepted For Presentation At Society For Neuro-Oncology 2021 Annual Meeting   Benzinga
09:15AM EST  Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting   PR Newswire
Nov 9, 2021
09:02AM EST  Lantern Pharma to Participate in Two Upcoming Investor Conferences   PR Newswire
Nov 4, 2021
09:41AM EDT  Lantern Pharma Announces Abstract On Effectiveness Of LP-284 In Hematologic Cancers Accepted For Presentation At The 63rd American Society Of Hematology Annual Meeting   Benzinga
09:38AM EDT  Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting   PR Newswire
Nov 2, 2021
10:47AM EDT  HC Wainwright & Co. Maintains Buy on Lantern Pharma, Raises Price Target to $34   Benzinga
10:24AM EDT  Lantern Pharma Q3 Net Loss $4.1M vs $1.7M In Same Qtr. Last Year   Benzinga
Nov 1, 2021
04:06PM EDT  Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating   PR Newswire
09:16AM EDT  Lantern Pharma's Proprietary A.I. Platform For Precision Oncology Drug Development, RADR, Surpasses 10 Billion Datapoints, Significantly Enhancing Precision Medicine Capabilities & Expanding Potential For Biopharma Collaborations And Partnerships   Benzinga
09:16AM EDT  Development, RADR(r), Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships   PR Newswire
04:01AM EDT  Earnings Scheduled For November 1, 2021   Benzinga
Oct 27, 2021
09:05AM EDT  Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology   PR Newswire
08:06AM EDT  Lantern Pharma Reports Collab With Code Ocean; Code Ocean Will Power AI-Driven Computational Research For Oncology-Focused Drug Discovery, No Terms Disclosed   Benzinga
08:03AM EDT  Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational   PR Newswire
Oct 25, 2021
04:58PM EDT  Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results   PR Newswire
Oct 7, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021   Benzinga
08:18AM EDT  HC Wainwright & Co. Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $32   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 29, 2021
12:10PM EDT  From BZ's Small Cap Healthcare Conference: Lantern Pharma President, Director & CEO, Panna Sharma Says Co Will Launch Its Ph 1/2 Clinical Trial For LP-184 In GBM In 2022   Benzinga
12:09PM EDT  From BZ's Small Cap Healthcare Conference: Lantern Pharma President, Director & CEO, Panna Sharma Says Co Will Launch Its Ph. 1 Clinical Trial For LP-184 In Solid Tumors In 2022   Benzinga
12:08PM EDT  From BZ's Small Cap Healthcare Conference: Lantern Pharma President, Director & CEO, Panna Sharma Says Co Will Launch Its Ph. 1 ADC Program In Solid Tumors In 2022   Benzinga
11:59AM EDT  From BZ's Small Cap Healthcare Conference: Lantern Pharma President, Director & CEO, Panna Sharma Says Co's Platform Is On Its Way To Reach 8 Billion Data Points, Says This Is Very Important For The Company   Benzinga
11:58AM EDT  From BZ's Small Cap Healthcare Conference: Lantern Pharma President, Director & CEO, Panna Sharma Says Co Leverages Its A.I Platform To Reduce Oncology Drug Development Costs And Improve The Likelihood Of Success   Benzinga
11:54AM EDT  From BZ's Small Cap Healthcare Conference: Lantern Pharma President, Director & CEO, Panna Sharma Begins Speaking   Benzinga
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 28, 2021
09:33AM EDT  Lantern- Deep Lens Partnership Expected To Accelerate Enrollment In Upcoming Phase 2 Trial For Never-Smokers With NSCLC   RTTNews
09:20AM EDT  Lantern Pharma Enters into Strategic Collaboration With Deep Lens; Terms Not Disclosed   Benzinga
09:20AM EDT  Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer   PR Newswire
Sep 22, 2021
09:14AM EDT  Lantern Pharma CEO To Present At Benzinga Healthcare Small Cap Conference On September 29th   Benzinga
09:01AM EDT  Lantern Pharma CEO to Present at the Benzinga Healthcare Small Cap Conference   PR Newswire
Sep 7, 2021
09:12AM EDT  Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences   PR Newswire
Sep 2, 2021
08:59AM EDT  Lantern Pharma Expands Management Team with Appointment of Two Leading Industry   PR Newswire
Aug 30, 2021
09:22AM EDT  Clinical-stage biopharmaceutical company Lantern Pharma (LTRN) said the FDA has granted LP-184 Orphan Drug Designation for the treatment of glioblastoma multiforme and other malignant gliomas. Previously, LP-184 was granted Orphan Drug Designation for the treatment of pancreatic cancer.   RTTNews
09:01AM EDT  FDA Grants Lantern Additional Orphan Drug Designation For LP-184 In Glioblastoma Multiforme & Malignant Gliomas   RTTNews
09:00AM EDT  FDA Grants Lantern Pharma Additional Orphan Drug Designation For Drug Candidate LP-184 In Glioblastoma Multiforme & Malignant Gliomas   Benzinga
08:59AM EDT  FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate   PR Newswire
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
09:34AM EDT  Lantern Pharma (LTRN) said a preclinical study has shown the company's drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma. The company said new data reinforces that LP-184 may have clinical utility for the treatment of primary and metastatic brain cancers.   RTTNews
08:53AM EDT  Lantern Pharma Announces Positive Preclinical Data In Glioblastoma With Drug Candidate LP-184; Stock Up   RTTNews
08:51AM EDT  Lantern Pharma Announces Preclinical Data In Glioblastoma (GBM) With Drug Candidate LP-184 And Expands GBM Research Collaboration   Benzinga
08:50AM EDT  Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with   PR Newswire
Aug 16, 2021
08:21AM EDT  Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference   Benzinga
08:20AM EDT  Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer   PR Newswire
Aug 11, 2021
04:51PM EDT  Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate   Benzinga
08:52AM EDT  Clinical stage biopharmaceutical company Lantern Pharma (LTRN) said the FDA has granted Orphan Drug Designation for LP-184 in the treatment of pancreatic cancer. LP-184 is a next-generation DNA-damaging agent being developed for pancreatic cancer in a collaboration with Fox Chase Cancer Center.   RTTNews
08:25AM EDT  FDA Grants Lantern Pharma Orphan Drug Designation For Drug Candidate LP-184 In Treatment Of Pancreatic Cancer; Stock Up   RTTNews
08:22AM EDT  FDA Grants Lantern Pharma Orphan Drug Designation For Drug Candidate LP-184 In The Treatment Of Pancreatic Cancer   Benzinga
08:22AM EDT  FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in   PR Newswire
Jul 30, 2021
12:40PM EDT  EXCLUSIVE: Lantern Pharma CEO, Panna L Sharma Says Around $2.5 Billion Is Spent On Pancreatic Cancer Therapy Globally, Says It Is $1 Billion In The U.S.   Benzinga
12:35PM EDT  EXCLUSIVE: Lantern Pharma CEO, Panna L Sharma Says Co Has 8 Million On Its Balance Sheet   Benzinga
12:31PM EDT  EXCLUSIVE: Lantern Pharma CEO, Panna L Sharma Now Interviewing On Benzinga's Power Hour Show   Benzinga
11:43AM EDT  EXCLUSIVE: Lantern Pharma CEO, Panna L Sharma To Appear On Benzinga's Power Hour Show At 12:30 p.m. EDT   Benzinga
08:53AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, Jul. 30, 2021: SAVA, PINS, ERYP, LTRN, UAA   Benzinga
Jul 29, 2021
04:42PM EDT  Lantern Pharma Q2 EPS $(0.21) Up From $(0.31) YoY   Benzinga
04:01PM EDT  Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational   PR Newswire
04:23AM EDT  Earnings Scheduled For July 29, 2021   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven from Allarity Therapeutics A/S; Lantern Will Pay $1M Upfront   Benzinga
11:13AM EDT  Lantern Pharma Enters Asset Purchase Agreement To Reacquire Global Development And Commercialization Rights To Irofulven From Allarity; Co. To Pay Initial Upfront Amount Of $1M, Allarity Eligible For Up Tp $16M   Benzinga
Jul 26, 2021
06:07AM EDT  A Peek Into The Markets: US Stock Futures Down Following Friday's Rally   Benzinga
05:14AM EDT  Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 22, 2021
04:09PM EDT  Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results   PR Newswire
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
08:12AM EDT  Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models   Benzinga
07:14AM EDT  Lantern Pharma Announces Positive Preclinical Data In Pancreatic Cancer With Drug Candidate LP-184   RTTNews
07:06AM EDT  Lantern Pharma Announces Preclinical Data In Pancreatic Cancer With Drug Candidate LP-184; Data Showed LP-184 Demonstrated Over 90% Pancreatic Tumor Shrinkage In In-Vivo Mouse Models In Eight Weeks   Benzinga
07:00AM EDT  Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic   PR Newswire
May 25, 2021
09:36AM EDT  Lantern Pharma - Using AI to Transform The Cost & Risk of Cancer Drug Development   Benzinga
May 12, 2021
12:11PM EDT  LTRN: 1Q:21 Results: 4.6 Billion Datapoints and Counting   Benzinga
May 3, 2021
04:49PM EDT  Lantern Pharma Q1 EPS $(0.24) Beats $(0.27) Estimate   Benzinga
04:33PM EDT  Lantern Pharma Reports First Quarter 2021 Financial Results and Operational   PR Newswire
08:27AM EDT  Lantern Pharma And Actuate Therapeutics Announce Research & Development Collaboration   RTTNews
07:20AM EDT  Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform   Benzinga
07:01AM EDT  Collaboration Leveraging Lantern's Artificial Intelligence Platform   PR Newswire
04:13AM EDT  Earnings Scheduled For May 3, 2021   Benzinga
Apr 29, 2021
07:27AM EDT  Lantern Pharma Reports Its Proprietary AI Platform For Precision Oncology Drug Development, RADR, Surpassed 4.6B Datapoints   Benzinga
07:02AM EDT  Development, RADR(r), Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's Strategy to Develop the World's Largest A.I. Platform for Oncology-Focused Drug Development & Rescue   PR Newswire
Apr 26, 2021
04:31PM EDT  Lantern Pharma to Host First Quarter 2021 Operating and Financial Results   PR Newswire
07:53AM EDT  Lantern Pharma Announces Publication Detailing Preclinical Results Of LP-184 In Journal Oncotarget   RTTNews
07:47AM EDT  Lantern Pharma Highlights Publication Detailing Preclinical Results Of Drug Candidate, LP-184 In The Journal Oncotarget   Benzinga
07:45AM EDT  Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget   PR Newswire
Apr 6, 2021
07:45AM EDT  Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare   PR Newswire
Apr 1, 2021
08:00AM EDT  Lantern Pharma Reports Collaboration With Johns Hopkins For Expansion Of Portfolio Of Cancer Opportunities For LP-184 For Pediatric Brain Tumor   Benzinga
07:59AM EDT  Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT   PR Newswire
Mar 25, 2021
02:45PM EDT  Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference   Benzinga
Mar 23, 2021
07:12PM EDT  Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021   Benzinga
07:50AM EDT  Lantern Pharma To Present Data Supporting Advancement Of LP-184 At AACR Virtual Annual Meeting 2021 Apr. 20-15   Benzinga
07:49AM EDT  Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the   PR Newswire
Mar 17, 2021
07:10AM EDT  Lantern Pharma Announces Filing Of Seven Patent Applications Globally On Novel DNA-Damaging Agent With Anticancer Properties   Benzinga
07:00AM EDT  Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel   PR Newswire
Mar 12, 2021
09:00AM EST  Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money   PR Newswire
Mar 10, 2021
04:01PM EST  Lantern Pharma Q4 EPS $(0.47) Misses $(0.45) Estimate; Says Had Cash And Equivalents Of $19.2M As Of Dec. 31   Benzinga
04:00PM EST  Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and   PR Newswire
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
04:04AM EST  Earnings Scheduled For March 10, 2021   Benzinga
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 3, 2021
07:01AM EST  Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and   PR Newswire
Feb 22, 2021
04:47PM EST  Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment   Benzinga
Jan 20, 2021
04:00PM EST  Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full   PR Newswire
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
05:49AM EST  Lantern Pharma Priced 4.2M Shares Public Offering @$14/Share   Benzinga
Jan 14, 2021
11:23PM EST  Lantern Pharma Prices Public Offering Of 4.29 Mln Shares At $14/Shr For Gross Proceeds Of $60 Mln   RTTNews
09:31PM EST  Lantern Pharma Announces Pricing of $60 Million Public Offering   PR Newswire
Jan 11, 2021
04:21AM EST  LTRN: Lantern Calls On Califia for Antibody Drug Conjugates   Benzinga
Jan 6, 2021
03:48PM EST  Lantern Pharma 8-K Shows Co., AF Chemicals Entered Second Addendum To Technology License Deal   Benzinga
Jan 4, 2021
08:44AM EST  Lantern Pharma Launches ADC Program To Target Solid Tumors & Blood Cancers Through Agreement With Califia Pharma   RTTNews
07:03AM EST  Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma   Benzinga
07:01AM EST  Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma   PR Newswire
Dec 29, 2020
10:23AM EST  Lantern Pharma's A.I. Platform Is Helping To Transform The Probability Of Success In Oncology Drug Development & Clinical Trials   Benzinga
Dec 17, 2020
07:45AM EST  Lantern Collaborates With Brain Cancer Program At Johns Hopkins To Further Develop LP-184 As Therapy For Glioblastoma   RTTNews
07:05AM EST  Lantern Pharma Reports Collaboration, Research Deal With Johns Hopkins Sidney Kimmel Cancer Center, Kennedy Krieger Institute For Development Of Co.'s LP-184 In Glioblastoma Multiforme   Benzinga
07:00AM EST  Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program   PR Newswire
Dec 15, 2020
07:14AM EST  Lantern: Data Indicates Blood Brain Barrier Permeability For Drug Candidate LP-184 In Glioblastoma And Other CNS Cancers   RTTNews
07:04AM EST  Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers   Benzinga
07:01AM EST  Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers   PR Newswire
Dec 8, 2020
08:33AM EST  Lantern Pharma's A.I. Platform Is Helping To Transform The Probability Of Success In Oncology Drug Development & Clinical Trials   Benzinga
Dec 7, 2020
10:58PM EST  The lockup period of Lantern Pharma Inc. (LTRN) ends Tuesday, i.e., on December 8, 2020.   RTTNews
Nov 24, 2020
07:30AM EST  Lantern Pharma Announces Upcoming Conference Presentations   PR Newswire
Oct 29, 2020
04:00PM EDT  Lantern Pharma Q3 EPS $(0.27) Beats $(0.33) Estimate   Benzinga
03:59PM EDT  Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued   PR Newswire
04:08AM EDT  Earnings Scheduled For October 29, 2020   Benzinga
Oct 22, 2020
07:01AM EDT  Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results   PR Newswire
Oct 5, 2020
07:47AM EDT  Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent   Benzinga
07:47AM EDT  with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent   PR Newswire
Sep 22, 2020
07:59AM EDT  Lantern Pharma Announces Collaboration Deal With Fox Chase Cancer Center For Development Of LP-184 In Pancreatic Cancer   RTTNews
07:55AM EDT  Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer   PR Newswire
07:55AM EDT  Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer   Benzinga
Aug 27, 2020
07:55AM EDT  Lantern Pharma Announces Upcoming Conference Presentations   PR Newswire
Aug 14, 2020
02:25PM EDT  Lantern Pharma Interview to Air on Bloomberg International on the RedChip Money   PR Newswire
08:26AM EDT  The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal   Benzinga
Aug 13, 2020
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
Jul 30, 2020
06:57AM EDT  Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued   PR Newswire
06:57AM EDT  Lantern Pharma Q2 EPS $(0.31) Up From $(0.32) YoY   Benzinga
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 28, 2020
09:56AM EDT  Colliers Securities Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $24   Benzinga
Jul 24, 2020
07:56AM EDT  Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results   PR Newswire
Jul 20, 2020
08:17AM EDT  Lantern In Deal With Groups To Advance Manufacturing And Development Activities On Both LP-300 And LP-184   RTTNews
08:14AM EDT  Lantern Establishes Manufacturing Network In Preparation For Phase 2 Trial For Treatment Of Non-Small Cell Lung Cancer   RTTNews
07:56AM EDT  Lantern Pharma Establishes Manufacturing Network In Preparation For Its Phase 2 Clinical Trial For Treatment Of Non-Small Cell Lung Cancer And Phase 1 Clinical Trial For Solid Tumors And Glioblastoma   Benzinga
07:55AM EDT  Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC